Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
- Six Partial Responses achieved to date in first 23 evaluable patients receiving the combination of sitravatinib and nivolumab for the treatment of checkpoint inhibitor refractory non-small cell lung cancer
- Tumor reductions observed in 19 of 23 evaluable patients
- 45 patients have been enrolled in the Phase 2 study, with plans to present more mature data at an oncology conference later this year
- Three Partial Responses achieved in the first 23 evaluable patients receiving the combination of mocetinostat and durvalumab for the treatment of checkpoint refractory non-small cell lung cancer
- To date, the combination has been well-tolerated and most adverse events (AEs) reported by investigators were Grade 1 or 2.
“The responses and duration of treatment seen with the combination of sitravatinib and a checkpoint inhibitor are very promising, notably because these patients had relapsed following prior checkpoint inhibitor therapy,” said Alexander Spira, M.D., Ph.D., Director of the Virginia Cancer Specialists Research Institute. “The trial is enrolling well, and we have been pleased with the favorable tolerability of the combination.”
